Development of allogeneic hematopoietic stem cell transplantation in 2022: Regenerating “Groot” to heal the world

Lv, Meng; Shen, Meng; Mo, Xiao‐Dong

doi:10.1016/j.xinn.2023.100373

Cited by 15 publications

(12 citation statements)

References 5 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IFN-α injections were administered subcutaneously twice or thrice a week. For patients older than 16 years, IFN-α injections were administered at dosages of 3 million units; for those younger than 16 years, they were administered at 3 million units IU/m ( 2 ) (capped by 3 million units). Patients should also undergo MRD monitoring after preemptive IFN-α treatment.…”

Section: Methodsmentioning

confidence: 99%

“…The primary endpoint was relapse, and the secondary endpoints included achieving MRD negative state, GVHD, NRM, LFS, and OS. To compare the characteristics of patients between groups, χ 2 and Fisher’s exact tests for categorical data and the Mann–Whitney U -test for continuous variable were performed. We used the Kaplan–Meier estimator to calculate the probabilities of OS and LFS.…”

Section: Methodsmentioning

confidence: 99%

“…Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the most important curative therapy for acute myeloid leukemia (AML) and can significantly improve the survival of these patients (1,2); however, relapse is still inevitable and is the most critical cause of treatment failure (3,4). Measurable residual disease (MRD; previously termed minimal residual disease) can predict forthcoming relapse (5)(6)(7)(8)(9), and MRD-directed treatment (i.e., preemptive treatment) is the most important method to prevent relapse after allo-HSCT (7,8).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Preemptive interferon-α therapy could prevent relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: A real-world analysis

et al. 2023

View full text Add to dashboard Cite

IntroductionMeasurable residual disease (MRD)-directed interferon-a treatment (i.e. preemptive IFN-α treatment) can eliminate the MRD in patients with acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Therefore, this study aimed to further assess its efficacy in a multicenter retrospective study in a real-world setting.MethodsA total of 247 patientswho received preemptive IFN-α treatment were recruited from 4 hospitals in China. The protocols for MRD monitoring mainly based on quantitative polymerase chain reaction [qPCR] and multiparameter flow cytometry [MFC]. ResultsThe median duration of IFN-α treatment was 56 days (range, 1–1211 days). The cumulative incidences of all grades acute graft-versus-host disease (aGVHD), all grades chronic graft-versus-host disease (cGVHD), and severe cGVHD at 3 years after IFN-α therapy were 2.0% (95% confidence interval [CI], 0.3–3.8%), 53.2% (95% CI, 46.8–59.7%), and 6.2% (95% CI, 3.1–9.2%), respectively. The cumulative incidence of achieving MRD negative state at 2 years after IFN-α treatment was 78.2% (95% CI, 72.6–83.7%). The 3-year cumulative incidences of relapse and non-relapse mortality following IFN-α therapy were 20.9% (95% CI, 15.5–26.3%) and 4.9% (95%CI, 2.0–7.7%), respectively. The probabilities of leukemia-free survival and overall survival at 3 years following IFN-α therapy were 76.9% (95% CI, 71.5–82.7%) and 84.2% (95% CI, 78.7–90.1%), respectively. Multivariable analysis showed that MRD positive state by qPCR and MFC before IFN-α treatment, high-risk disease risk index before allo-HSCT, and receiving identical sibling donor HSCT were associated with a higher risk of relapse and a poorer leukemia-free survival. Severe cGVHD was associated with an increased risk of non-relapse mortality. DiscussionThus, real-world data suggest that preemptive IFN-α is effective for treating patients with AML with MRD after allo-HSCT.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Preemptive interferon-α therapy could prevent relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: A real-world analysis

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Allogeneic haematopoietic stem cell transplantation (allo‐HSCT) is one of the most important curative methods for AML 5,6 . Several studies reported that AYAs could benefit from identical sibling donor (ISD) HSCT, particularly for those from intermediate‐risk group 3,7 .…”

Section: Introductionmentioning

confidence: 99%

“…4 Thus, these patients are considered as a distinct patient subgroup within acute leukaemia.Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is one of the most important curative methods for AML. 5,6 Several studies reported that AYAs could benefit from identical sibling donor (ISD) HSCT, particularly…”

mentioning

confidence: 99%

Outcomes of haploidentical haematopoietic stem cell transplantation for adolescent and young adults with acute myeloid leukaemia

Huo

Zhang

et al. 2023

Br J Haematol

View full text Add to dashboard Cite

SummaryWe aimed to identify the efficacy of haploidentical related donor (HID) haematopoietic stem cell transplantation (HSCT) in adolescent and young adults (AYAs) with acute myeloid leukaemia (AML) in a large cohort. Consecutive AML AYAs (15–39 years old, n = 599) receiving HID HSCT in complete remission (CR) were included. The 3‐year cumulative incidence of measurable residual disease occurrence, relapse and non‐relapse mortality after HID HSCT was 28.6% (95% CI: 25.0–32.2), 11.6% (95% CI: 9.0–14.2) and 6.7% (95% CI: 4.7–8.7) respectively. The 3‐year probability of event‐free survival, leukaemia‐free survival (LFS) and overall survival (OS) after HID HSCT was 60.7% (95% CI: 56.9–64.8), 81.7% (95% CI: 78.7–84.9) and 85.6% (95% CI: 82.8–88.4) respectively. In multivariable analysis, AML risk category at diagnosis and comorbidity burdens before HID HSCT were independently associated with LFS and OS. Compared to the older adults (≥ 40 years, n = 355) with AML receiving HID HSCT in CR during the same time period, AYAs have a lower incidence of non‐relapse mortality and higher probabilities of LFS and OS. Thus, we firstly confirmed the safety and efficacy of HID HSCT in AYAs with AML‐CR.

show abstract

Clinical characteristics and outcomes of allogeneic hematopoietic stem cell transplantation recipients with coronavirus disease 2019 caused by the Omicron variant: a prospective, observational cohort study

Fan,

Mo,

Zhang

et al. 2024

Ann Hematol

View full text Add to dashboard Cite

Development of allogeneic hematopoietic stem cell transplantation in 2022: Regenerating “Groot” to heal the world

Cited by 15 publications

References 5 publications

Preemptive interferon-α therapy could prevent relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: A real-world analysis

Preemptive interferon-α therapy could prevent relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: A real-world analysis

Outcomes of haploidentical haematopoietic stem cell transplantation for adolescent and young adults with acute myeloid leukaemia

Clinical characteristics and outcomes of allogeneic hematopoietic stem cell transplantation recipients with coronavirus disease 2019 caused by the Omicron variant: a prospective, observational cohort study

Contact Info

Product

Resources

About